An FDA advisory committee voted 11-0 in favor of expanding the label of Carvykti, finding that the benefits of the Johnson & Johnson treatment outweigh risks in early myeloma, according to media coverage of the panel.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Foot Locker appoints Cindy Carlisle as Chief Human Resources Officer
- Neumora Therapeutics price target raised to $31 from $24 at RBC Capital
- Johnson & Johnson put volume heavy and directionally bearish
- Ambrx Biopharma shareholders approve acquisition by Johnson & Johnson
- High Benzene Levels Found in Multiple Brands’ Acne Treatments
